
|Videos|December 28, 2022
Dr. Magee on use of exogenous testosterone in patients with localized prostate cancer
Author(s)Urology Times staff
“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.
Advertisement
In this video, Diana Magee, MD, MPH, MSc, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Use of exogenous testosterone in the setting of screening, active surveillance, and after treatment of localized disease.” Magee is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5


















